Viracta Therapeutics, Inc. (VIRX)

0.8102 -0.0298 (-3.55%) At close: 04:00PM EDT

Viracta Therapeutics, Inc.

2533 South Coast Highway 101
Suite 210
Cardiff, CA 92007
United States
858 400 8470
https://www.viracta.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 40

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mark Andrew Rothera	CEO, President & Director	959.33k	N/A	1963
Dr. Darrel P. Cohen M.D., Ph.D.	Chief Medical Officer	576.51k	N/A	1965
Dr. Susan Perrine M.D.	Scientific Founder and Consultant	N/A	N/A	N/A
Dr. Ronald J. Berenson M.D.	Co-Founder and Consultant	N/A	N/A	1952
Mr. George Hillman	Co-Founder	N/A	N/A	N/A
Dr. Thalia Papayannopoulou M.D.	Co-Founder	N/A	N/A	N/A
Dr. Robert M. Williams Ph.D.	Co-Founder	N/A	N/A	1955
Dr. Douglas V. Faller M.D., Ph.D.	Scientific Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Ms. Melody Burcar C.P.A., M.B.A.	Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer	N/A	N/A	1983
Dr. Ayman El-Guindy	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Corporate Governance

Viracta Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.